Compile Data Set for Download or QSAR
Report error Found 367 for UniProtKB: Q13794
LigandPNGBDBM571467((+)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3...)
Affinity DataIC50: 0.260nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM562371(US11401278, Example 44 | US11401278, Example 46 | ...)
Affinity DataIC50: 0.310nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM571478((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.330nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM562369(US11401278, Example 42 | (−)-4-chloro-14-cyc...)
Affinity DataIC50: 0.340nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM562401(US11401278, Example 72 | 4-chloro-3-ethyl-7-{3-[(6...)
Affinity DataIC50: 0.340nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM571483((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.370nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571511((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.370nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571480((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 0.390nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM562377(US11401278, Example 48 | US11401278, Example 65 | ...)
Affinity DataIC50: 0.400nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM571489((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.410nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571514((+)-4-chloro-15-[2-(3,3-difluoroazetidin-1-yl)ethy...)
Affinity DataIC50: 0.420nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 0.450nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM571497(4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox...)
Affinity DataIC50: 0.460nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571525((+)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluor...)
Affinity DataIC50: 0.460nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM572155((rac)-4-chloro-3-ethyl-1-[2-(morpholin-4-yl)ethyl]...)
Affinity DataIC50: 0.470nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM562386(US11401278, Example 57 | (+)-4-chloro-3,14-diethyl...)
Affinity DataIC50: 0.480nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM571473((rac)-4-chloro-(15-rac)-(2-methoxyethyl)-2,3-dimet...)
Affinity DataIC50: 0.480nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571486((+)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.480nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM572162(US11478451, Example 17 | (+)-4-chloro-7-{3-[(6-flu...)
Affinity DataIC50: 0.490nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM562331(US11401278, Example 4 | US11401278, Example 5 | (r...)
Affinity DataIC50: 0.520nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM571477((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 0.520nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM572159((+)-4-chloro-2,3,14-trimethyl-7-[3-(naphthalen-1-y...)
Affinity DataIC50: 0.520nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM571449(US11440923, Example 15 | US11440923, Example 14 | ...)
Affinity DataIC50: 0.530nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571522((+)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluor...)
Affinity DataIC50: 0.530nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571446((rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4...)
Affinity DataIC50: 0.540nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571502((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.540nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571481((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.550nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571443(US11440923, Example 9 | US11440923, Example 8 | (r...)
Affinity DataIC50: 0.570nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM562401(US11401278, Example 72 | 4-chloro-3-ethyl-7-{3-[(6...)
Affinity DataIC50: 0.590nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM572181((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.590nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM572166(US11478451, Example 21 | (rac)-4-chloro-3-ethyl-2-...)
Affinity DataIC50: 0.590nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM562363(US11401278, Example 36 | (+)-4-chloro-3-ethyl-7-{3...)
Affinity DataIC50: 0.600nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM571528((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)...)
Affinity DataIC50: 0.600nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM572152(US11478451, Example 7 | (rac)-4-chloro-3-ethyl-7-{...)
Affinity DataIC50: 0.600nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM571459((+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-y...)
Affinity DataIC50: 0.630nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM562383(US11401278, Example 54 | (+)-4-chloro-14-cycloprop...)
Affinity DataIC50: 0.640nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM571528((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)...)
Affinity DataIC50: 0.640nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571443(US11440923, Example 9 | US11440923, Example 8 | (r...)
Affinity DataIC50: 0.660nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM572161(US11478451, Example 16 | US11447504, Example 16 | ...)
Affinity DataIC50: 0.660nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM571496((rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1...)
Affinity DataIC50: 0.690nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM572173(US11478451, Example 27 | US11447504, Example 27 | ...)
Affinity DataIC50: 0.690nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM572219(US11447504, Example 76 | US11447504, Example 75 | ...)
Affinity DataIC50: 0.700nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM572178(US11478451, Example 32 | (+)-4-chloro-7-{3-[(6-flu...)
Affinity DataIC50: 0.710nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM572192(US11478451, Example 47 | (rac)-4-chloro-3-ethyl-14...)
Affinity DataIC50: 0.710nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM571446((rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4...)
Affinity DataIC50: 0.720nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571475((+)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluor...)
Affinity DataIC50: 0.720nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM571471((+)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(na...)
Affinity DataIC50: 0.730nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

LigandPNGBDBM562379(US11401278, Example 50 | (rac)-4-chloro-7-{3-[(6-f...)
Affinity DataIC50: 0.740nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
Go to US Patent

LigandPNGBDBM572196((+)-4-chloro-3-methyl-2-[3-(4-methylpiperazin-1-yl...)
Affinity DataIC50: 0.75nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM571491((rac)-4-chloro-(15-rac)-[2-(3,3-difluoropyrrolidin...)
Affinity DataIC50: 0.780nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/19/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 367 total ) | Next | Last >>
Jump to: